Fludarabine‐containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients
暂无分享,去创建一个
G. Martinelli | S. Tura | P. Tosi | N. Testoni | G. Visani | M. Motta | P. Piccaluga | S. Rizzi | P. Ricci | R. Lemoli | R. Pastano | A. Dizdari | G. Leopardi
[1] S. Tura,et al. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study , 1999, Bone Marrow Transplantation.
[2] G. Martinelli,et al. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods , 1998, Bone Marrow Transplantation.
[3] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[4] J. Román,et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome , 1998, Bone Marrow Transplantation.
[5] S. Tura,et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. , 1997, Experimental hematology.
[6] H. Döhner,et al. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony‐stimulating factor‐supported high‐dose cytarabine and mitoxantrone , 1997, British journal of haematology.
[7] C. Sawyers,et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission , 1997, Leukemia.
[8] B. Cheson,et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Storb,et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. , 1996, Bone marrow transplantation.
[10] W. Hiddemann,et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.
[11] F. Gherlinzoni,et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. , 1996, Leukemia.
[12] G. Martinelli,et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. , 1996, Blood.
[13] S. Singhal,et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. , 1995, Bone marrow transplantation.
[14] P. Zinzani,et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. , 1994, Leukemia.
[15] A. Tedeschi,et al. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. , 1994, Leukemia & lymphoma.
[16] P. Thall,et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Sanz,et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Richard J. Jones. Autologous bone marrow transplantation , 1993, Current opinion in oncology.
[19] L. To,et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.
[20] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Tosi,et al. Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying hematological recovery. , 1990, Cryobiology.
[22] P. Sonneveld,et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Oscier,et al. RELAPSE AFTER AUTOGRAFTING WITH PERIPHERAL BLOOD STEM CELLS , 1988, The Lancet.
[24] L. Douay,et al. RELAPSE AFTER AUTOGRAFTING WITH PERIPHERAL BLOOD STEM CELLS , 1987, The Lancet.
[25] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[26] F. Patrone,et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. , 1996, Haematologica.
[27] B. Löwenberg,et al. High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice? , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R. Holle,et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. , 1991, Bone marrow transplantation.
[29] M. Labopin,et al. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. The EBMT Group Working Party for Autologous Bone Marrow Transplantation. , 1991, Bone marrow transplantation.
[30] F. Herrmann,et al. Minimal peripheral blood cells carrying clonal markers of B cell disorders: evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma. , 1989, International journal of cell cloning.
[31] R. Raijmakers,et al. Autologous bone-marrow transplantation. , 1987, Lancet.